SCHEMBL4222269

SCHEMBL4222269

O=C(O)C=Cc1ccc(NC2CCN(C(=O)c3ccccc3)CC2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.53
NOS1 P29475 1/20 0.53
NOS2 P35228 1/20 0.53
EPHX1 P07099 2/20 0.50
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
NAMPT P43490 1/20 0.48
GPR183 P32249 1/20 0.47
ALDH1A1 P00352 1/20 0.47
POLB P06746 1/20 0.47
TSHR P16473 1/20 0.47
JAK1 P23458 1/20 0.45
CCNK O75909 5/20 0.45
CDK12 Q9NYV4 5/20 0.45
ACHE P22303 1/20 0.44
CCNA2 P20248 2/20 0.43
CDK2 P24941 2/20 0.43
CDK7 P50613 2/20 0.43
CCNH P51946 2/20 0.43
MNAT1 P51948 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4222260 1.00 NOS3 (0.53) NOS3NOS1NOS2EPHX1CYP3A4
SCHEMBL4218980 0.90 NOS3 (0.53) NOS3NOS1NOS2GPR183CCNK
SCHEMBL4219143 0.90 CCNK (0.52) NOS3NOS1NOS2GPR183CCNK
SCHEMBL4223760 0.90 PRKAA2 (0.52) NOS3NOS1NOS2POLBCCNK
SCHEMBL4218987 0.90 NOS3 (0.53) NOS3NOS1NOS2GPR183CCNK
SCHEMBL4219134 0.90 CCNK (0.52) NOS3NOS1NOS2GPR183CCNK
SCHEMBL4223767 0.90 PRKAA2 (0.52) NOS3NOS1NOS2POLBCCNK
Hydrochloric Acid SCHEMBL4227486 0.89 HDAC6 (0.52) NOS3NOS1NOS2EPHX1CYP3A4
Hydrochloric Acid SCHEMBL4227490 0.89 HDAC6 (0.52) NOS3NOS1NOS2EPHX1CYP3A4
SCHEMBL4218914 0.89 SLC6A7 (0.47) NOS3NOS1NOS2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557127-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2009-07-07 US disclosed
US-20090054464-A1 HDAC INHIBITOR ASTELLAS PHARMA INC. (JP) 2009-02-26 US disclosed
US-7465731-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2008-12-16 US disclosed
US-20060052599-A1 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052599-A1 HDAC inhibitor HDAC1, HDAC2, HDAC11 NOS3 4122/4885NOS1 3471/4885NOS2 3761/4885
US-20090054464-A1 HDAC INHIBITOR HDAC1, HDAC2, HDAC8 NOS3 4184/4885NOS1 3647/4885NOS2 3815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.